Home › Compound Library › Mirena IUD (Levonorgestrel 52mg)

Mirena IUD (Levonorgestrel 52mg)

Hormonal Contraceptiveprescriptionintrauterine · inferred

Levonorgestrel-releasing intrauterine device (52 mg) providing contraception for up to 8 years. Releases ~20 mcg/day initially, declining to ~10 mcg/day by year 5. Primarily local effect; systemic LNG levels are very low. Also treats heavy menstrual bleeding.

Projected serum levels — 1 device (≈ 52 mg), custom (shown daily)

Mirena IUD (Levonorgestrel 52mg)
Mirena IUD (Levonorgestrel 52mg) modeled serum levels, 1 device (≈ 52 mg) custom (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 14 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 14
Mirena IUD (Levonorgestrel 52mg) modeled serum levels with a loading dose of 3 device, then 1 device (≈ 52 mg) custom (shown daily) The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 1 device (≈ 52 mg) custom (shown daily) (intrauterine).

Loading schedule: 3 device on day 1, then 1 device (≈ 52 mg) custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~14 days: peak ≈ 1.1 mg, trough ≈ 1.1 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormonal Contraceptive
Route modeled
Intrauterine
Model confidence
inferred
Half-life
15 h
Common dose
1 device (≈ 52 mg)
Suggested maximum
1 device/day
Reference dose range
0.50–1 device (single dose)
Suggested cadence
custom (shown daily)
Validated against
52 mg td — Cmax 0.000 mg/L at 720 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Mirena IUD (Levonorgestrel 52mg) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Mirena IUD (Levonorgestrel 52mg) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Mirena IUD (Levonorgestrel 52mg) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~5.00x

  • contraindicated
    Diltiazem + Mirena IUD (Levonorgestrel 52mg) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Mirena IUD (Levonorgestrel 52mg) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Mirena IUD (Levonorgestrel 52mg) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Mirena IUD (Levonorgestrel 52mg) AUC by ~10.00x

Serum checks 256 modeled interaction pairings for mirena iud (levonorgestrel 52mg) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Levonorgestrel-Releasing Intrauterine System (Mirena) for Contraception and Beyond Luukkainen T, Toivonen J · Contraception, 1995 DOI

    Foundational review of the LNG-IUS showing >99% efficacy, 20 mcg/day initial release, primarily local endometrial action, and non-contraceptive benefits for menorrhagia.

  2. Intrauterine Devices: An Effective Alternative to Oral Hormonal Contraception Hubacher D et al. · New England Journal of Medicine, 2009 DOI

    NEJM review establishing modern IUDs as first-line contraception with failure rates <1%, including LNG-IUS pharmacology and systemic absorption data.

  3. Long-Term Safety and Efficacy of the 52 mg Levonorgestrel-Releasing Intrauterine System Gemzell-Danielsson K et al. · Contraception, 2017 DOI

    Extended 8-year efficacy data showing sustained contraceptive effect with cumulative Pearl Index <0.5 and progressive reduction in menstrual bleeding.

3 published studies referenced in the app, each with a plain-language summary.